FDA nominee: "no political pressure"

26 March 2006

Speaking at the Association of Health Care Journalists annual meeting, Andrew von Eschenbach, who has been nominated by President George W Bush to head the US Food and Drug Administration, said that he has not been "restrained or constrained" when it came to making scientific decisions. His comment came in response to a question on the perception that the Bush administration has used political pressure in asking doctors to place a higher value on ideology than on scientific evidence, according to a report carried by Reuters.

Dr von Eschenbach, who has led the FDA temporarily since last September - while also serving as director of the National Cancer Institute - suggested that a discussion needs to be ongoing about the implications of these scientific discoveries, and that society as a whole needs to be in on the deliberations. Commenting on his work at both agencies, he noted that "we are moving toward an effort to bring the full fruits of this biomedical research enterprise to patients as rapidly...as possible, ensuring the balance between what is effective, and what is safe and what is appropriate."

While Senators Hillary Rodham Clinton and Patty Murray have already said they plan to block the nomination until the agency finally makes a decision on Plan B, Dr Von Eschenbach declined to discuss this issue or any points relating to the agency, other than the comment on the absence of political pressure. First, he said, he needed to share his vision of the FDA with Congress.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight